Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Shirish M GadgeelM C Garassino

Abstract

In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression. We report an updated analysis from KEYNOTE-189 (ClinicalTrials.gov: NCT02578680). Patients were randomly assigned (2:1) to receive pemetrexed and platinum plus pembrolizumab (n = 410) or placebo (n = 206) every 3 weeks for 4 cycles, then pemetrexed maintenance plus pembrolizumab or placebo for up to a total of 35 cycles. Eligible patients with disease progression in the placebo-combination group could cross over to pembrolizumab monotherapy. Response was assessed per RECIST (version 1.1) by central review. No alpha was assigned to this updated analysis. As of September 21, 2018 (median follow-up, 23.1 months), the updated median (95% CI) OS was 22.0 (19.5 to 25.2) months in the pembrolizumab-combination group versus 10.7 (8.7 to 13.6) months in the placebo-combination group (hazard ratio [HR], 0.56; 95% CI, 0.45 to 0.70]). Median (95% CI) PFS was 9.0 (8.1 to 9.9) months and 4.9 (4.7 to 5.5) month...Continue Reading

References

Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
May 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio Vittorio ScagliottiDavid Gandara
Jun 1, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stanleyson V HatoW Joost Lesterhuis
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Apr 17, 2018·The New England Journal of Medicine·Matthew D HellmannLuis Paz-Ares
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
Jun 5, 2018·The New England Journal of Medicine·Mark A SocinskiUNKNOWN IMpower150 Study Group
Aug 4, 2018·Medical Oncology·Amanda Jane Williams GibsonWinson Y Cheung
Aug 24, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hossein BorghaeiLeena Gandhi
Oct 4, 2018·The New England Journal of Medicine·Luis Paz-AresUNKNOWN KEYNOTE-407 Investigators
Aug 15, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David A SchaerRuslan D Novosiadly

❮ Previous
Next ❯

Citations

Jun 23, 2020·Pharmacogenomics·Sylvie Brassart-PascoJean-Baptiste Oudart
Jun 6, 2020·Future Oncology·Maria Virginia BluthgenGonzalo Recondo
Aug 9, 2020·OncoTargets and Therapy·Sneha GullapalliGilberto Lopes
Aug 18, 2020·OncoTargets and Therapy·Wei LiuJianhui Cai
May 10, 2020·British Journal of Clinical Pharmacology·Vishal NavaniAndre Van Der Westhuizen
Oct 13, 2020·Expert Opinion on Investigational Drugs·Si-Yang Liu, Yi-Long Wu
Nov 12, 2020·Pharmaceuticals·Nicola J NasserAbed Agbarya
Nov 25, 2020·Current Opinion in Oncology·Georg Pall
Dec 15, 2020·Critical Reviews in Oncology/hematology·Evgeny N ImyanitovEvgeny V Levchenko
Jan 21, 2021·Current Oncology·D Gwyn BebbMing-Sound Tsao
Feb 14, 2021·Nature Reviews. Clinical Oncology·Deborah Blythe DoroshowFred R Hirsch
Dec 3, 2020·Journal of Clinical Medicine·Shigeki Suzuki, Taichiro Goto
Oct 27, 2020·Frontiers in Oncology·Evgeny N ImyanitovIlya V Tsimafeyeu
Dec 18, 2020·Frontiers in Oncology·Tomasz KubiatowskiPaweł Krawczyk
Jan 31, 2021·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Hardik ShethSewanti Limaye
Oct 30, 2020·Respirology : Official Journal of the Asian Pacific Society of Respirology·Alistair Miller, Emily Stone
Feb 2, 2021·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Tianqing ChuBaohui Han
Dec 17, 2020·Frontiers in Oncology·Lin ZhangQing Geng
Feb 18, 2021·Journal of Surgical Oncology·Gabriela Bravo MontenegroStephen V Liu
Sep 27, 2020·Cancer Treatment Reviews·Jordi RemonBenjamin Besse
Feb 27, 2021·International Journal of Cancer. Journal International Du Cancer·Jia Li LowWei Peng Yong
Dec 18, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Makoto NishioMark A Socinski
Mar 5, 2021·Clinical Lung Cancer·Guilherme HaradaGilberto de Castro Junior
Mar 2, 2021·Therapeutic Advances in Medical Oncology·Jingjing QuJianying Zhou
Mar 8, 2021·The AAPS Journal·Julianne D Twomey, Baolin Zhang
Mar 18, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Edward B GaronShirish M Gadgeel

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.